PRF Technologies (PRFX) Cash from Financing Activities (2020 - 2023)
PRF Technologies' (PRFX) quarterly Cash from Financing Activities came in at $1.0 million in Q4 2023, down 71.56% on a QoQ basis from $3.6 million in Q3 2023.
PRF Technologies (PRFX) Cash from Financing Activities (2020 - 2023) Analysis & Trends
PRF Technologies (PRFX) has 3 years of Cash from Financing Activities data on file, last reported at $1.0 million in Q4 2023.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $1.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $6.5 million (changed N/A YoY) and the FY2025 annual result came in at $3.8 million, down 56.92% from the prior year.
- Cash from Financing Activities eased to $1.0 million in Q4 2023, from $3.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $7.5 billion in Q3 2021 to a low of -$7.5 billion in Q4 2021.
- A 3-year average of $4.9 million and a median of $4.6 million in 2021 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 42899.34% in 2021, down 42899.34% in 2021.
- Tracing PRFX's Cash from Financing Activities over 3 years: stood at $17.4 million in 2020, then plunged by 43088.25% to -$7.5 billion in 2021, then soared by 100.01% to $1.0 million in 2023.
- The last three Cash from Financing Activities figures came in at $1.0 million (Q4 2023), $3.6 million (Q3 2023), and -$7.5 billion (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | PRF Technologies | 647,973.00 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.02 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Dec 31, 2021 | -7.48 Bn |
| Dec 31, 2021 | -7.48 Bn |
| Sep 30, 2021 | 7.48 Bn |
| Sep 30, 2021 | 7.48 Bn |
| Mar 31, 2021 | 5.55 Mn |
| Mar 31, 2021 | 5.55 Mn |
| Sep 30, 2020 | 17.39 Mn |
| Sep 30, 2020 | 17.39 Mn |